There are some key differences that set CLL apart from other types of leukemia, such as ALL ... acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) -- start in myeloid cells in ...

However, we found that most acute myeloid leukemia (AML ... in reduction of SOCS1 protein levels and partial differentiation of AML cells. AML cells with inactivated RIP1/RIP3 signaling show ...

Conventional cytogenetic analysis in the newly diagnosed leukemia patient relies on the presence of mitotically active dividing cells ... which are common in AML, ALL and CML.

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

and keeping new blood cells from being made. As they continue to grow, they can spread to your blood and build up in your organs. CLL gets worse slowly, and many people don't have symptoms at first.

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in cancer immunotherapy.The team discovered a unique population of immune cells ...

In this study, we demonstrated that insufficient erythropoiesis in an immunocompetent acute myeloid leukemia ... inhibited erythroid differentiation of hematopoietic stem cells, common myeloid ...